Anika Therapeutics Inc (ANIK) - Total Liabilities
Based on the latest financial reports, Anika Therapeutics Inc (ANIK) has total liabilities worth $46.80 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Anika Therapeutics Inc (ANIK) cash conversion ratio to assess how effectively this company generates cash.
Anika Therapeutics Inc - Total Liabilities Trend (1993–2025)
This chart illustrates how Anika Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check ANIK cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Anika Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Anika Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DAE-IL Corporation
KO:092200
|
Korea | ₩551.84 Billion |
|
Veritone Inc
NASDAQ:VERI
|
USA | $184.20 Million |
|
Montauk Renewables Inc
NASDAQ:MNTK
|
USA | $122.58 Million |
|
Sif Holding NV
AS:SIFG
|
Netherlands | €515.54 Million |
|
Gwangjushinseg
KO:037710
|
Korea | ₩397.59 Billion |
|
MacroGenics Inc
NASDAQ:MGNX
|
USA | $201.25 Million |
|
Hengyuan Refining Company Bhd
KLSE:4324
|
Malaysia | RM3.59 Billion |
|
Pyridam Farma Tbk
JK:PYFA
|
Indonesia | Rp6.19 Trillion |
Liability Composition Analysis (1993–2025)
This chart breaks down Anika Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Anika Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anika Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anika Therapeutics Inc (1993–2025)
The table below shows the annual total liabilities of Anika Therapeutics Inc from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $46.80 Million | -3.99% |
| 2024-12-31 | $48.75 Million | -16.48% |
| 2023-12-31 | $58.37 Million | -8.18% |
| 2022-12-31 | $63.56 Million | +5.15% |
| 2021-12-31 | $60.45 Million | -35.14% |
| 2020-12-31 | $93.20 Million | +120.18% |
| 2019-12-31 | $42.33 Million | +175.22% |
| 2018-12-31 | $15.38 Million | -19.58% |
| 2017-12-31 | $19.13 Million | +9.46% |
| 2016-12-31 | $17.47 Million | -29.83% |
| 2015-12-31 | $24.90 Million | +56.61% |
| 2014-12-31 | $15.90 Million | -22.09% |
| 2013-12-31 | $20.41 Million | -38.43% |
| 2012-12-31 | $33.14 Million | -12.97% |
| 2011-12-31 | $38.08 Million | -12.95% |
| 2010-12-31 | $43.75 Million | -9.91% |
| 2009-12-31 | $48.56 Million | +38.48% |
| 2008-12-31 | $35.06 Million | +42.91% |
| 2007-12-31 | $24.54 Million | +8.44% |
| 2006-12-31 | $22.63 Million | -8.49% |
| 2005-12-31 | $24.73 Million | -15.25% |
| 2004-12-31 | $29.18 Million | +650.19% |
| 2003-12-31 | $3.89 Million | +28.67% |
| 2002-12-31 | $3.02 Million | +7.49% |
| 2001-12-31 | $2.81 Million | +24.08% |
| 2000-12-31 | $2.27 Million | -66.67% |
| 1999-12-31 | $6.80 Million | +172.00% |
| 1998-12-31 | $2.50 Million | 0.00% |
| 1997-12-31 | $2.50 Million | +31.58% |
| 1996-12-31 | $1.90 Million | -13.64% |
| 1995-12-31 | $2.20 Million | -4.35% |
| 1994-12-31 | $2.30 Million | -20.69% |
| 1993-12-31 | $2.90 Million | -- |
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-op… Read more